Genetic Testing (PGT/PGD) in Noida: A Complete Clinical Guide for IVF Patients

Preimplantation Genetic Testing (PGT) is an embryo-screening procedure performed during an IVF cycle before the embryo is transferred to the uterus. Its predecessor term, Preimplantation Genetic Diagnosis (PGD), is still widely used by patients and clinicians in India. The procedure involves removing a few cells from the outer layer (trophectoderm) of a blastocyst-stage embryo and sending them to a certified genetics laboratory for chromosomal or gene-specific analysis.

There are three main subtypes: PGT-A screens for aneuploidy (abnormal chromosome number, such as trisomy 21); PGT-M tests for monogenic or single-gene disorders like thalassaemia — a condition with notably high carrier frequency in parts of Uttar Pradesh; and PGT-SR is used when one partner carries a structural chromosomal rearrangement such as a translocation. For Noida couples who have already experienced failed IVF cycles or second-trimester losses, understanding which subtype applies to their situation is the first clinical step.

HomeIVF Medical Board clinicians guide patients through this classification during an initial consultation, ensuring testing is not over-ordered or under-ordered — a problem that remains surprisingly common in generic fertility setups across the NCR region.

Not every IVF patient in Noida requires PGT, but certain clinical profiles make it strongly advisable. Women aged 37 and above face a significantly higher rate of chromosomally abnormal embryos — in this group, aneuploidy rates can exceed 50–60% of blastocysts, making PGT-A a logical investment before transfer. Couples who have suffered two or more unexplained miscarriages, or those who have had two or more failed euploid-quality embryo transfers, are also strong candidates.

Carriers of autosomal recessive conditions such as beta-thalassaemia — which has elevated prevalence in families with roots in western Uttar Pradesh and parts of Gujarat — should request PGT-M before conceiving through IVF. Similarly, if either partner carries a balanced chromosomal translocation identified on a karyotype report, PGT-SR is the appropriate test to avoid transferring unbalanced embryos.

Families in Greater Noida and Noida Extension seeking fertility treatment for a second child after having a child with a known genetic disorder are increasingly using PGT-M to prevent recurrence. HomeIVF coordinates with empanelled genetics labs to arrange pre-cycle probe preparation — a process that can take 8–12 weeks and must be planned well in advance of egg retrieval.

The genetic burden relevant to Noida's patient population reflects both urban migration patterns and the ancestral diversity of Uttar Pradesh. Beta-thalassaemia major remains the most frequently tested monogenic condition in PGT-M cycles coordinated by HomeIVF in this geography. Sickle-cell anaemia, cystic fibrosis, spinal muscular atrophy (SMA), and Duchenne muscular dystrophy are also among the conditions for which certified Indian labs offer validated probe panels.

On the chromosomal side, PGT-A routinely identifies trisomies (13, 18, 21), monosomies, and complex polyploidies that would otherwise result in failed implantation or early miscarriage. For patients who have undergone standard karyotyping in hospitals near Sector 18 or Sector 62 and received a report of a balanced translocation, PGT-SR provides the next layer of reproductive safety.

HomeIVF Medical Board also advises patients with a family history of hereditary breast and ovarian cancer (BRCA1/BRCA2 mutations) to consider PGT-M, allowing them to select embryos free of the mutation before pregnancy. This intersection of oncofertility and genetic testing is a growing area of clinical demand in Noida's well-informed, professionally active patient community.

Understanding the procedural timeline reduces anxiety significantly for Noida patients embarking on their first PGT cycle. The process begins with ovarian stimulation — identical to a standard IVF cycle — using injectable gonadotrophins for approximately 10–12 days. Follicle growth is monitored through ultrasound and bloodwork, which HomeIVF coordinates at empanelled diagnostic centres near your locality, whether you are in Sector 62, Greater Noida, or Noida Extension.

Once mature follicles are confirmed, egg retrieval (oocyte pick-up) is performed under short-acting anaesthesia. Retrieved eggs are fertilised in the embryology laboratory using conventional IVF or ICSI. Embryos are cultured to the blastocyst stage (Day 5 or 6), at which point an embryologist performs a trophectoderm biopsy — removing 5–8 cells from the outer layer without harming the inner cell mass that becomes the baby.

Biopsied cells are sent via temperature-controlled courier to a certified genetics laboratory. Results arrive in 10–14 working days. Embryos are vitrified (frozen) during this waiting period. Once results confirm which embryos are euploid or unaffected, a frozen embryo transfer (FET) cycle is planned. HomeIVF Medical Board reviews all results with patients in a structured genetic counselling session before any transfer decision is made.

Cost is one of the most frequently searched concerns for Noida patients researching PGT. It is important to understand that genetic testing adds a layer of expenditure beyond standard IVF, primarily because of the specialised laboratory work involved in biopsy, vitrification, genetics analysis, and a subsequent FET cycle. HomeIVF offers IVF packages starting from ₹1.5 lakh, with PGT-A and PGT-M add-ons priced transparently and explained in detail during your free initial consultation — so there are no hidden surprises.

The overall timeline for a PGT cycle from stimulation start to embryo transfer typically spans 10–14 weeks when accounting for stimulation, biopsy, genetic analysis, and FET preparation. Patients in Greater Noida or Noida Extension should plan for this extended window and factor it into leave planning and work commitments.

HomeIVF's Noida coordination model means that many monitoring visits — ultrasounds, bloodwork — happen at empanelled centres close to your home, reducing the burden of travel to central Delhi-NCR. All clinical decisions, including cycle optimisation and transfer timing, are managed by the HomeIVF Medical Board, ensuring senior specialist oversight throughout the extended PGT timeline.

One of the most distinctive aspects of HomeIVF's approach is its home-monitoring infrastructure, which is particularly valuable for patients undergoing the longer PGT pathway. During ovarian stimulation, patients typically need 4–6 monitoring ultrasounds over 10–12 days. For a working professional in Sector 62 or a family residing in Noida Extension, making repeated trips to a central hospital in Delhi can mean lost working hours, traffic stress, and childcare complications.

HomeIVF coordinates monitoring visits at NABL-accredited diagnostic partners located within Noida and Greater Noida, with results reviewed same-day by the HomeIVF Medical Board. Medication adjustments are communicated via the HomeIVF app, and nursing support is available for patients who require assistance with injectable stimulation medications at home.

This model does not compromise on clinical depth. HomeIVF delivers senior-specialist care at home — not a reduced version of it. Genetic counselling sessions, result interpretation calls, and transfer planning consultations are all conducted by qualified senior clinicians assigned through the HomeIVF Medical Board. For patients who have previously felt overwhelmed by impersonal hospital systems in NCR, this continuity of care represents a meaningful clinical and emotional advantage during a demanding treatment cycle.

Despite Noida's status as a technologically advanced city, several real barriers prevent couples from accessing PGT appropriately. The first is awareness: many patients seen in general gynaecology clinics around Sector 18 and Greater Noida are not informed about PGT even when their clinical profile — recurrent miscarriage, advanced maternal age, family history of genetic disease — clearly warrants it.

The second barrier is fragmentation. A patient may get karyotyping done at one lab, genetic counselling at a hospital in Delhi, IVF stimulation at another clinic, and biopsy elsewhere — with no single provider coordinating the chain. This fragmentation introduces delays, miscommunications, and missed steps like probe preparation for PGT-M, which must begin 8–12 weeks before egg retrieval.

HomeIVF removes these barriers through its integrated coordination model. From the first consultation, a dedicated case manager links the genetics lab, the embryology partner, the monitoring network, and the HomeIVF Medical Board into a single clinical pathway. Patients receive a written cycle plan, a WhatsApp support line, and a named counsellor — replacing fragmentation with coherent, accountable care. For Noida families who have spent months navigating disconnected advice, this integrated structure is often the decisive reason they choose HomeIVF.

While HomeIVF respects patient confidentiality and does not publish individual case details, the HomeIVF Medical Board has identified recurring patient archetypes in Noida for whom PGT has been clinically transformative.

The first archetype is the 'recurrent loss couple' — typically in their early-to-mid thirties, having suffered two or three unexplained miscarriages after natural conception or IUI. PGT-A on their embryos frequently identifies that a significant proportion carry chromosomal abnormalities, explaining prior losses and allowing the team to transfer only chromosomally normal embryos.

The second is the 'carrier couple' — both partners identified as beta-thalassaemia carriers during routine premarital screening, a practice increasingly common in Greater Noida's educated urban population. PGT-M allows them to select unaffected embryos and avoid passing on the condition to their child.

The third is the 'advanced age IVF patient' — a woman aged 38–42 in Noida Extension or Sector 62 who has generated multiple blastocysts but experienced failed transfers. PGT-A gives her and her clinical team the confidence to transfer the embryo with the highest likelihood of success, rather than guessing based on morphology alone. In all three archetypes, the common thread is that PGT converted uncertainty into actionable clinical information.